A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)

Eiji Oki, A. Murata, K. Yoshida, K. Maeda, K. Ikejiri, Y. Munemoto, K. Sasaki, C. Matsuda, M. Kotake, T. Suenaga, H. Matsuda, Y. Emi, Y. Kakeji, H. Baba, C. Hamada, S. Saji, Yoshihiko Maehara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Backgrounds: Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer. Patients and methods: The ACTS-RC trial was an open-label, randomized, phase III superiority trial conducted at 222sites in Japan. Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year. The primary end point was relapse-free survival (RFS), and the secondary end points were overall survival and adverse events. Results: In total, 961 patients were enrolled from April 2006 to March 2009. The primary analysis was conducted in 480 assigned to receive UFT and 479 assigned to receive S-1. Five-year RFS was 61.7% [95% confidence interval (CI) 57.1% to 65.9%] for UFT and 66.4% (95% CI 61.9% to 70.5%) for S-1 [P = 0.0165, hazard ratio (HR): 0.77, 95% CI 0.63-0.96].Five-year survival was 80.2% (95% CI 76.3% to 83.5%) for UFT and 82.0% (95% CI 78.3% to 85.2%) for S-1. The main grade 3 or higher adverse events were increased alanine aminotransferase and diarrhea (each 2.3%) in the UFT arm and anorexia, diarrhea (each 2.6%), and fatigue (2.1%) in the S-1 arm. Conclusion: One-year S-1 treatment is superior to UFT with respect to RFS and has therefore become a standard adjuvant chemotherapy regimen for stage II/III rectal cancer following curative resection.

Original languageEnglish
Article numbermdw162
Pages (from-to)1266-1272
Number of pages7
JournalAnnals of Oncology
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Adjuvant Chemotherapy
Rectal Neoplasms
Confidence Intervals
Survival
Recurrence
Diarrhea
Japan
Tegafur
Uracil
Anorexia
Alanine Transaminase
Fatigue
1-UFT protocol
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1 : ACTS-RC). / Oki, Eiji; Murata, A.; Yoshida, K.; Maeda, K.; Ikejiri, K.; Munemoto, Y.; Sasaki, K.; Matsuda, C.; Kotake, M.; Suenaga, T.; Matsuda, H.; Emi, Y.; Kakeji, Y.; Baba, H.; Hamada, C.; Saji, S.; Maehara, Yoshihiko.

In: Annals of Oncology, Vol. 27, No. 7, mdw162, 01.07.2016, p. 1266-1272.

Research output: Contribution to journalArticle

Oki, E, Murata, A, Yoshida, K, Maeda, K, Ikejiri, K, Munemoto, Y, Sasaki, K, Matsuda, C, Kotake, M, Suenaga, T, Matsuda, H, Emi, Y, Kakeji, Y, Baba, H, Hamada, C, Saji, S & Maehara, Y 2016, 'A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)', Annals of Oncology, vol. 27, no. 7, mdw162, pp. 1266-1272. https://doi.org/10.1093/annonc/mdw162
Oki, Eiji ; Murata, A. ; Yoshida, K. ; Maeda, K. ; Ikejiri, K. ; Munemoto, Y. ; Sasaki, K. ; Matsuda, C. ; Kotake, M. ; Suenaga, T. ; Matsuda, H. ; Emi, Y. ; Kakeji, Y. ; Baba, H. ; Hamada, C. ; Saji, S. ; Maehara, Yoshihiko. / A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1 : ACTS-RC). In: Annals of Oncology. 2016 ; Vol. 27, No. 7. pp. 1266-1272.
@article{2436635016eb40929e99d78fdf7df649,
title = "A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)",
abstract = "Backgrounds: Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer. Patients and methods: The ACTS-RC trial was an open-label, randomized, phase III superiority trial conducted at 222sites in Japan. Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year. The primary end point was relapse-free survival (RFS), and the secondary end points were overall survival and adverse events. Results: In total, 961 patients were enrolled from April 2006 to March 2009. The primary analysis was conducted in 480 assigned to receive UFT and 479 assigned to receive S-1. Five-year RFS was 61.7{\%} [95{\%} confidence interval (CI) 57.1{\%} to 65.9{\%}] for UFT and 66.4{\%} (95{\%} CI 61.9{\%} to 70.5{\%}) for S-1 [P = 0.0165, hazard ratio (HR): 0.77, 95{\%} CI 0.63-0.96].Five-year survival was 80.2{\%} (95{\%} CI 76.3{\%} to 83.5{\%}) for UFT and 82.0{\%} (95{\%} CI 78.3{\%} to 85.2{\%}) for S-1. The main grade 3 or higher adverse events were increased alanine aminotransferase and diarrhea (each 2.3{\%}) in the UFT arm and anorexia, diarrhea (each 2.6{\%}), and fatigue (2.1{\%}) in the S-1 arm. Conclusion: One-year S-1 treatment is superior to UFT with respect to RFS and has therefore become a standard adjuvant chemotherapy regimen for stage II/III rectal cancer following curative resection.",
author = "Eiji Oki and A. Murata and K. Yoshida and K. Maeda and K. Ikejiri and Y. Munemoto and K. Sasaki and C. Matsuda and M. Kotake and T. Suenaga and H. Matsuda and Y. Emi and Y. Kakeji and H. Baba and C. Hamada and S. Saji and Yoshihiko Maehara",
year = "2016",
month = "7",
day = "1",
doi = "10.1093/annonc/mdw162",
language = "English",
volume = "27",
pages = "1266--1272",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1

T2 - ACTS-RC)

AU - Oki, Eiji

AU - Murata, A.

AU - Yoshida, K.

AU - Maeda, K.

AU - Ikejiri, K.

AU - Munemoto, Y.

AU - Sasaki, K.

AU - Matsuda, C.

AU - Kotake, M.

AU - Suenaga, T.

AU - Matsuda, H.

AU - Emi, Y.

AU - Kakeji, Y.

AU - Baba, H.

AU - Hamada, C.

AU - Saji, S.

AU - Maehara, Yoshihiko

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Backgrounds: Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer. Patients and methods: The ACTS-RC trial was an open-label, randomized, phase III superiority trial conducted at 222sites in Japan. Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year. The primary end point was relapse-free survival (RFS), and the secondary end points were overall survival and adverse events. Results: In total, 961 patients were enrolled from April 2006 to March 2009. The primary analysis was conducted in 480 assigned to receive UFT and 479 assigned to receive S-1. Five-year RFS was 61.7% [95% confidence interval (CI) 57.1% to 65.9%] for UFT and 66.4% (95% CI 61.9% to 70.5%) for S-1 [P = 0.0165, hazard ratio (HR): 0.77, 95% CI 0.63-0.96].Five-year survival was 80.2% (95% CI 76.3% to 83.5%) for UFT and 82.0% (95% CI 78.3% to 85.2%) for S-1. The main grade 3 or higher adverse events were increased alanine aminotransferase and diarrhea (each 2.3%) in the UFT arm and anorexia, diarrhea (each 2.6%), and fatigue (2.1%) in the S-1 arm. Conclusion: One-year S-1 treatment is superior to UFT with respect to RFS and has therefore become a standard adjuvant chemotherapy regimen for stage II/III rectal cancer following curative resection.

AB - Backgrounds: Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer. Patients and methods: The ACTS-RC trial was an open-label, randomized, phase III superiority trial conducted at 222sites in Japan. Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year. The primary end point was relapse-free survival (RFS), and the secondary end points were overall survival and adverse events. Results: In total, 961 patients were enrolled from April 2006 to March 2009. The primary analysis was conducted in 480 assigned to receive UFT and 479 assigned to receive S-1. Five-year RFS was 61.7% [95% confidence interval (CI) 57.1% to 65.9%] for UFT and 66.4% (95% CI 61.9% to 70.5%) for S-1 [P = 0.0165, hazard ratio (HR): 0.77, 95% CI 0.63-0.96].Five-year survival was 80.2% (95% CI 76.3% to 83.5%) for UFT and 82.0% (95% CI 78.3% to 85.2%) for S-1. The main grade 3 or higher adverse events were increased alanine aminotransferase and diarrhea (each 2.3%) in the UFT arm and anorexia, diarrhea (each 2.6%), and fatigue (2.1%) in the S-1 arm. Conclusion: One-year S-1 treatment is superior to UFT with respect to RFS and has therefore become a standard adjuvant chemotherapy regimen for stage II/III rectal cancer following curative resection.

UR - http://www.scopus.com/inward/record.url?scp=84977079614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977079614&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw162

DO - 10.1093/annonc/mdw162

M3 - Article

C2 - 27056996

AN - SCOPUS:84977079614

VL - 27

SP - 1266

EP - 1272

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

M1 - mdw162

ER -